Tumor cell proliferation inhibitors

A high α-type mannose inhibitor derived from natural sources effectively suppresses tumor cell growth with minimal side effects, addressing the cytotoxicity issues of current inhibitors and ensuring targeted tumor cell accumulation.

JP7580699B1Active Publication Date: 2024-11-12MEIS TECH CO LTD +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024113159
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-12
Estimated Expiration
2044-07-16

AI Technical Summary

Technical Problem

Current tumor cell proliferation inhibitors, such as chemical substances, exhibit cytotoxicity to both tumor and normal cells, leading to significant side effects, and orally administered mannose does not accumulate specifically in tumor cells, necessitating large doses with side effects like diarrhea and vaginal hot flashes.

Method used

A tumor cell proliferation inhibitor containing mannose with a high ratio of α-type to β-type, derived from natural sources like konjac potato, effectively suppresses tumor cell growth with minimal side effects by ensuring high α-mannose content, preferably 70% or more, through enzymatic hydrolysis and purification.

Benefits of technology

The inhibitor achieves a strong tumor cell proliferation inhibitory effect with reduced dosage requirements, is safe for consumption, and effectively targets tumor cells without harming normal cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580699000001
    Figure 0007580699000001
  • Figure 0007580699000002
    Figure 0007580699000002
  • Figure 0007580699000003
    Figure 0007580699000003
Patent Text Reader

Abstract

The present invention addresses the problem of providing a tumor cell proliferation inhibitor for use in the prevention and / or treatment of cancer, which contains mannose and has a higher tumor cell proliferation inhibitory effect, thereby eliminating the need to ingest large amounts of mannose. [Solution] The present invention provides a tumor cell growth inhibitor containing mannose with a high ratio of α-type mannose, which is effective for the prevention and / or treatment of cancer. The tumor cell growth inhibitor of the present invention has a stronger tumor cell growth inhibitory effect than conventionally known mannose, and furthermore, because it is derived from natural raw materials, it can be safely ingested or administered.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a tumor cell proliferation inhibitor, specifically to a tumor cell proliferation inhibitor for use in the prevention and / or treatment of cancer, which contains as an active ingredient D-mannose having a higher α-type than β-type. [Background technology]

[0002] According to a survey by the Ministry of Health, Labor and Welfare, the number one cause of death among Japanese people is malignant neoplasms (tumors), far ahead of heart disease, which is the second most common cause. Reflecting this, many recent research results have led to progress in elucidating the mechanisms of tumor development. These research results have revealed that various chemical substances can control the development and growth of tumors, and they are used for medicinal purposes as antitumor agents. However, while the various chemical substances used have strong antitumor effects, they also exhibit cytotoxicity not only to tumor cells but also to normal cells, and side effects are a major problem. Therefore, there is a need for a highly safe tumor cell growth inhibitor that has very little cytotoxicity and suppresses the growth of only tumor cells.

[0003] It is well known that tumor cells have an active cellular metabolism. In particular, tumor cells have the property of consuming large amounts of sugar compared to normal cells. Many tumor cells have enhanced glucose uptake, and this property is used in cancer screening, known as PET examination. PET examinations use FDG (fluorodeoxyglucose), which has a structure similar to glucose, to detect FDG accumulated in cells and identify the presence and location of tumor cells. As such, because of the enhanced glucose uptake in tumor cells, research is also being conducted on reactions to monosaccharides other than glucose. For example, mannose is taken up into tumor cells by the same transporter as glucose, but it is known to accumulate in the cells as mannose-6-phosphate and inhibit further metabolism of glucose in glycolysis, the tricarboxylic acid cycle, the pentose phosphate pathway, and sugar chain synthesis. As a result, it has been reported that mannose causes the inhibition of proliferation of many types of tumor cells and promotes cell death in response to major chemotherapy (see, for example, Non-Patent Document 1).

[0004] Mannose exists in D- and L-forms, but since the L-form does not exist in nature, D-mannose is referred to as mannose in this specification. Furthermore, mannose exists as α- and β-type stereoisomers (anomers). When the hydroxyl group on the C1 carbon and the hydroxymethyl group on the C5 carbon are in the opposite directions, it is called α-type, and when they are in the same direction, it is called β-type. In general, in an aqueous solution, the anomers are interconverted between each other as mannopyranose, and the α-type and β-type exist in equilibrium.

[0005] Currently, most mannose used in foods and other products is produced by isomerizing glucose using a molybdic acid catalyst (see, for example, Patent Document 1), but it has been reported that when this isomerized mannose is dissolved in an aqueous solution, the α- and β-types reach equilibrium over time, with the α-type and β-type being approximately 67% and 33%, respectively. When mannose is crystallized from methanol, the α-type is obtained, and when it is crystallized using glacial acetic acid, the β-type is obtained. However, even crystallized mannose, when placed in an aqueous solution, will reach equilibrium over time with the α- and β-types reaching the above ratio (see, for example, Non-Patent Documents 2 and 3). [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Special Publication No. 63-12072 [Non-patent literature]

[0007] [Non-Patent Document 1] Pablo Sierra Gonzalez, et. al., “Mannose impairs tumor growth and enhances chemotherapy” NATURE, vol 563, 719-723 (2018) [Non-Patent Document 2] The Merck Index, published January 1, 2006, 14th edition, p5747 [Non-Patent Document 3] Chemistry Encyclopedia, Morikita Publishing, November 2012, 2nd Edition, "Mannose" Summary of the Invention [Problem to be solved by the invention]

[0008] Orally administered mannose is absorbed from the small intestine and delivered throughout the body via the bloodstream, where it exerts an inhibitory effect on the proliferation of various tumor cells, but it does not accumulate specifically in tumor cells. Therefore, in order to increase the mannose concentration throughout the body, it was necessary to ingest large amounts of mannose, but it has been reported that ingesting large amounts of mannose causes diarrhea and vaginal hot flashes as side effects in some cases.

[0009] An object of the present invention is to provide a tumor cell proliferation inhibitor for use in the prevention and / or treatment of cancer, which contains mannose having a higher tumor cell proliferation inhibitory effect, thereby eliminating the need to ingest large amounts of mannose. [Means for solving the problem]

[0010] Means for Solving the Problems The present inventors have conducted extensive research to achieve the above object, and as a result have discovered that mannose having a high ratio of α-mannose has a high inhibitory effect on tumor cell proliferation, thereby completing the present invention.

[0011] That is, the present invention provides the following (1) to ( 6 ) is the gist of this paper. (1) The ratio of α-mannose to total mannose is 70% or more Less than 80% Mannose, At least one hydrolyzate selected from the group consisting of mannan, glucomannan, galactomannan, and natural products containing them. A tumor cell proliferation inhibitor for use in the prevention and / or treatment of cancer, comprising the above compound as an active ingredient. (2) The glucomannan is derived from konjac root. 1 ) A tumor cell proliferation inhibitor as described above. (3) The tumor cell proliferation inhibitor according to (1), wherein the cancer is a cancer of the digestive system. (4) The tumor cell proliferation inhibitor according to (1), wherein the cancer is colon cancer. (5) (1) A tumor cell proliferation inhibitor comprising the tumor cell proliferation inhibitor according to the present invention. For inhibiting tumor cell proliferation Medicines or quasi-drugs. (6) (1) A tumor cell proliferation inhibitor comprising the tumor cell proliferation inhibitor according to the present invention. For inhibiting tumor cell proliferation Food and drink composition. Effect of the Invention

[0012] The tumor cell proliferation inhibitor of the present invention contains a large amount of α-mannose, and therefore has an excellent tumor cell proliferation inhibitory effect, and can be used for the prevention and / or treatment of cancer. Because of its high tumor cell proliferation inhibitory effect, it can be expected to be effective even with a small amount of administration. Furthermore, by using mannose derived from a natural product, it can be safely ingested or administered. [Brief description of the drawings]

[0013] [Figure 1] Glucomannan-derived mannose inhibits cell proliferation in colon cancer spheroids (cell line: HC6T strain) [Diagram 2] Glucomannan-derived mannose inhibits cell proliferation in colon cancer spheroids (cell line: HC106T) [Diagram 3] Glucomannan-derived mannose inhibits cell proliferation in colon cancer spheroids (cell line: HC108T strain) DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The present invention will be described in detail below. The tumor cell proliferation inhibitor of the present invention contains, as an active ingredient, mannose in which the ratio of α-mannose to the total mannose is 70% or more, preferably 75% or more, and more preferably 80% or more. If the ratio is less than 70%, the tumor cell proliferation inhibitor does not exhibit a high tumor cell proliferation inhibitory effect. Furthermore, "containing as an active ingredient" means containing an amount of mannose effective for prevention or treatment, and includes being acceptable for animal and human medicinal use. Since mannose exists in α- and β-types, the "ratio of α-mannose to total mannose" here refers to the weight ratio of α-type / (α-type + β-type) calculated from the GC area when measured under the following conditions.

[0015] (Method for measuring the ratio of α-mannose to total mannose) 12 mL of pyridine, 8 mL of 1,1,1,3,3,3-hexamethyldisilazane, and 4 mL of chlorotrimethylsilane were added to 0.5 g of mannose, and the mixture was dissolved by shaking, and then allowed to stand at room temperature for 4 hours. The mixture was filtered through a 0.45 μm filter, and the filtrate was analyzed by gas chromatography under the following conditions. (Gas Chromatography Measurement Conditions) Analytical column: Low polarity column chemically bonded with 5% diphenyl-95% dimethylpolysiloxane (length 30 m x inner diameter 0.32 mm x film thickness 0.4 μm) Heating conditions: Heat from 110°C to 250°C at 5°C / min, then hold at 250°C for 5 minutes Sample introduction temperature: 250℃ Carrier gas: Helium Column gas flow rate: 2.0 mL / min Detector and detection temperature: Hydrogen flame ionization detector, 250℃ Injection port: (Temperature) 250℃, (Injection volume) Split 1μL (Split ratio: 30:1)

[0016] The origin of the mannose used in the present invention is not important, but mannose produced from natural products is preferred from the viewpoint of safety. As the raw material of such mannose, at least one selected from the group consisting of mannan, glucomannan, galactomannan, and natural products containing them is preferred. Specific raw materials are not particularly limited as long as they contain mannan, glucomannan, and galactomannan as constituent sugars, and examples thereof include coconut, palm, and its oil extraction residue (copra meal, palm kernel meal, etc.), ivory palm (seed), konjac root and its processed products (rough flour, refined flour, flying powder, etc.), guar beans and its processed products (guar gum, etc.), coffee beans or its extraction residue (coffee grounds, etc.), locust beans and its processed products (carob powder, locust bean gum, etc.). Among these, it is preferred to use konjac root and its processed products from the viewpoint of containing a large amount of the constituent sugars and from the viewpoint of low cost. The natural product may be used as a raw material as it is, or may be purified. A mixture of these may also be used.

[0017] In the present invention, in order to produce mannose having a high ratio of the α-type, a method of obtaining mannose by hydrolyzing at least one selected from the group consisting of mannan, glucomannan, galactomannan, and natural products containing them is preferred. When hydrolyzing at least one selected from the group consisting of mannan, glucomannan, galactomannan, and natural products containing them, it is possible to carry out hydrolysis using an acid, an alkali, an enzyme, or the like, or under a high-temperature and high-pressure environment. Among these, hydrolysis using an enzyme is preferred in terms of the small amount of by-products, the small restrictions on the equipment in the hydrolysis step, and the small burden on the environment.

[0018] The enzyme used in the above-mentioned enzymatic treatment in the present invention is not particularly limited as long as it has the activity of acting on at least one selected from the group consisting of mannan, glucomannan, galactomannan, and natural products containing them to release monosaccharides, but for example, enzymes that act on the main chain of hemicellulose to release monosaccharides, such as mannanase, galactomannanase, glucomannanase, mannosidase, α-xylidase, xyloglucanase, arabinanase, β-xylosidase, xylanase, α-arabinofuranosidase, cellulase, etc., are preferred. Among them, mannan-decomposing enzymes such as mannanase, mannosidase, or galactomannanase are preferred.

[0019] If necessary, glucosidase, galactosidase, etc., which are enzymes that liberate glucose, galactose, etc. present in the branched side chains of hemicellulose, can be used in combination with the enzyme acting on the main chain. Furthermore, the mannose yield can be increased by mixing two or more types of enzymes with different activities. In addition, the enzyme to be used may be any fraction having mannose liberating activity in the culture of the strain from which the enzyme originates, and if necessary, fractions containing these enzymes can be purified or partially purified by conventional methods before use.

[0020] The reaction conditions for releasing mannose by allowing the enzyme to act on at least one selected from the group consisting of mannan, glucomannan, galactomannan, and natural products containing them can be selected as optimal conditions according to each enzyme. The reaction temperature is preferably performed under conditions that do not inactivate the enzyme, and is, for example, 30 to 70°C, preferably 40 to 60°C, and more preferably 50 to 60°C. The reaction time also depends on conditions such as the amount of enzyme used, but is usually preferably set between 3 hours and 72 hours for operational reasons. Furthermore, the reaction pH depends on the type of enzyme used, and is, for example, preferably 2 to 9, more preferably 2.5 to 8, and more preferably 3 to 6.

[0021] The liberated mannose may be purified to further increase the purity of mannose. Purification may be performed by known methods, such as decolorization using bone charcoal, activated charcoal, carbonation, adsorption resin, magnesia method, etc., and desalting and deacidification using ion exchange resin, ion exchange membrane, electrodialysis, etc. The combination of purification methods and purification conditions may be appropriately selected depending on the amounts of pigments, salts, acids, etc. in the mannose-containing reaction solution and other factors.

[0022] The form of the mannose of the present invention is not particularly limited, and examples thereof include an aqueous solution containing mannose, a powder, etc. To obtain a powder, known techniques such as solid-liquid separation, resin purification, membrane purification, concentration, spray drying, freeze drying, and crystallization can be used.

[0023] The tumor cell proliferation inhibitor of the present invention is used for the prevention and / or treatment of cancer. The use for the prevention and / or treatment of cancer means use for at least one of the following purposes: suppression of cancer progression in a patient suffering from cancer, suppression of cancer or tumor growth, prevention of cancer onset, and prevention of cancer recurrence.

[0024] The types of cancers that are the subject of the present invention are not particularly limited, but include cancers of the digestive system (e.g., colorectal cancer (including colon cancer, colon adenocarcinoma, and rectal cancer), oral cancer, pharyngeal cancer, esophageal cancer, stomach cancer, liver cancer, gallbladder cancer, biliary tract cancer, spleen cancer, small intestine cancer, duodenal cancer, pancreatic cancer, and liver cancer), cancers of the nervous system (e.g., brain tumors and cervical cancer), cancers of the musculoskeletal system (e.g., sarcoma, osteosarcoma, and myeloma), cancers of the urinary system (e.g., bladder cancer and kidney cancer), and cancers of the reproductive system (e.g., breast cancer, uterine cancer, ovarian cancer, testicular cancer, and prostate cancer). , respiratory system cancer (e.g., lung cancer), hematopoietic system cancer (e.g., leukemia such as acute or chronic myeloid leukemia, acute promyelocytic leukemia, acute or chronic lymphocytic leukemia, malignant lymphoma (lymphosarcoma), angiosarcoma, multiple myeloma, myelodysplastic syndrome, primary myelofibrosis, hemangiopericytoma), thyroid cancer, parathyroid cancer, tongue cancer, malignant melanoma, mast cell tumor, cutaneous histiocytoma, lipoma, hair follicle tumor, skin papilloma, sebaceous adenoma, basal cell carcinoma, etc. Among these, application to digestive system cancer is preferred, and application to colon cancer is more preferred.

[0025] The dosage of the tumor cell proliferation inhibitor of the present invention can be appropriately adjusted taking into consideration the purpose of use, the subject of administration, the gender, age, weight, and stage of progression of cancer of the subject. This dosage varies depending on various conditions, so in some cases a small dosage or number of administrations is sufficient, and in other cases a large dosage or number of administrations is required. The administration regime may be a single administration or frequent administration, but frequent administration is preferred because the effect is sustained if the administration is continued. The concentration of mannose to be administered is preferably 2.5 mM to 200 mM, more preferably 4 mM to 150 mM.

[0026] The dosage form of the tumor cell proliferation inhibitor of the present invention is not particularly limited, and may be, for example, oral administration preparations (tablets, coated tablets, powders, granules, capsules, liquids, etc.), airway administration preparations, intraperitoneal administration preparations, intravenous administration preparations, injections, suppositories, patches, ointments, etc., with oral administration preparations, airway administration preparations, or intravenous administration preparations being preferred. Intravenous administration preparations include intravenous injection preparations and drip intravenous injection preparations. In humans, oral administration preparations or intravenous administration preparations are preferred.

[0027] For preparation, the tumor cell proliferation inhibitor of the present invention may be mixed with non-toxic, inactive, medicamentically acceptable excipients, such as solid, semi-solid or liquid diluents, dispersants, fillers and carriers, as necessary.Furthermore, within the range that does not impair the effects of the present invention, stabilizers, preservatives, pH adjusters, binders, disintegrants, surfactants, lubricants, flow enhancers, flavorings, colorants, flavoring preservatives, media, physiological saline, and other medicinal drugs may be included as additives.

[0028] When the tumor cell proliferation inhibitor of the present invention is administered, it may be administered in combination with other cancer therapeutic agents or therapies. Treatment methods that can be used in combination with the tumor cell proliferation inhibitor of the present invention include chemotherapy, radiation therapy, chemoradiotherapy, immunotherapy, hormone therapy, surgery, or stem cell therapy. Among them, chemotherapy is preferred, and examples of chemotherapeutic agents that are preferably used in chemotherapy include, but are not limited to, platinum chemotherapy agents, anthracycline therapeutic agents, or alkylating chemotherapy agents. Among them, cisplatin is preferred as a platinum chemotherapy agent, and doxorubicin is preferred as an anthracycline therapeutic agent. Concomitant administration refers to administration simultaneously with administration of the tumor cell proliferation inhibitor of the present invention, or before or after administration of the tumor cell proliferation inhibitor of the present invention. Alternatively, the tumor cell proliferation inhibitor of the present invention and the other cancer therapeutic agent may be mixed to form a single preparation. EXAMPLES

[0029] The present invention will be specifically described with reference to the following examples, but the present invention is not limited to these.

[0030] <Analysis of α- and β-mannose> 0.5 g of the sample was weighed out and placed in a 25 mL measuring flask, and 12 mL of pyridine, 8 mL of 1,1,1,3,3,3-hexamethyldisilazane, and 4 mL of chlorotrimethylsilane were added. The mixture was shaken to dissolve, and then allowed to stand for 4 hours. Insoluble matter was removed from this solution using a 0.45 μm filter to prepare a sample for analysis. GC analysis was performed under the following conditions. The weight ratio of α-type to β-type was determined from the GC area, and the ratio of α-type mannose to total mannose was calculated. Equipment: Agilent Technologies 7890B GC System Column: INERT CAP-5 (30m x 0.32mm ID, film thickness 0.4μm) Heating conditions: Heat from 110°C to 250°C at 5°C / min, then hold at 250°C for 5 minutes Sample introduction temperature: 250℃ Carrier gas: Helium Column gas flow rate: 2.0 mL / min Detector and detection temperature: Hydrogen flame ionization detector, 250℃ Injection port: (Temperature) 250℃, (Injection volume) Split 1μL (Split ratio: 30:1)

[0031] <Production of mannose derived from glucomannan> The enzyme reaction was started by adding 10 mL of ion-exchanged water containing 25 mg of mannanase (Amano Enzyme Co., Ltd., Mannanase BGM "Amano") dissolved therein to 1 g of glucomannan (refined flour) refined from konjac yam. After 48 hours of enzyme treatment at 58°C, the enzyme was inactivated at 96°C for 10 minutes. After filtering using filter paper (No. 5C) to remove water-insoluble matter, the mixture was concentrated using a rotary evaporator to produce a sugar solution with a mannose concentration of 40 g / 100 g. EXAMPLES

[0032] The weight ratio of α-type to β-type was analyzed for the sugar solution containing glucomannan-derived mannose obtained above (24 hours or more after production). As a result, the ratio of α-type to β-type calculated from the GC area was 80% and 20%, and mannose with a large amount of α-type was obtained. Next, using the colon cancer spheroid HC6T strain, the reactivity to the colon cancer spheroid was performed by image analysis using the glucomannan-derived mannose obtained above. All experiments were performed three independent times. The colon cancer spheroids were derived from colon cancer patients. In the present invention, the HC6T strain (Kyoto University strain, the same applies to other strains below) was used. The above spheroids that had been frozen and stored were thawed and cultured to an appropriate cell amount. The medium used was Advanced DMEM / F12 (Thermo Fisher), 5% FBS, 10 μM Y27632, 1 μM SB431542, 50 ng / ml EGF, 100 ng / ml FGF-basic, 100 units / ml penicillin, 0.1 mg / ml streptomycin, 2 mM L-glutamine, and 5 g / ml Plasmocin (Invivogen, San Diego, CA). Cells for drug sensitivity testing were seeded into 96-well plates (TPP_96F) at 800 cells / well in 4 wells. The glucomannan-derived mannose obtained above was added to the medium so that the mannose concentration was 125 mM. The day after seeding was designated Day 0, and images were taken on Day 3 using a Cell3 imager duos [SCREEN holdings, model CC-8000, software ver.1.6 Rev.2.0.1]. Using Manual Focus mode, 61% of the center of the well was set as the imaging range (the size that the entire gel fits within the range), and continuous cross-sectional images were taken at 15 points every 50 μm in the z-axis direction, and output as fully focused images. The reaction was started by changing the medium on Day 0. After that, the culture was continued without changing the medium until the end of the experiment. The imaging interval was set to be almost constant. The Measure function of the analysis software [SCREEN holdings, software ver.1.6 Rev.2.0.1] was used to apply the program to the spheroid image data to calculate the area value. Furthermore, the volume data was calculated from the calculated area value using the program software R. When calculating the volume data, a program was used that calculates the radius from the area, calculates the volume of the sphere from the radius value, and calculates the total volume value per well. The volume ratio was calculated from the volume value Day 3 / Day 0, and the ratio of each concentration was calculated and compared when the control was set to 1. The volume ratio (Day 3 / Day 0) of each data point was calculated from the obtained volume data. A t-test was used to test for significant differences with the control group. A p value of less than 0.05 was considered to indicate a significant difference. The results are shown in Figure 1. The vertical axis GEI in Figure 1 stands for growth effect index. Comparative Example 1

[0033] For mannose (Tokyo Chemical Industry Co., Ltd.), which is sold as a reagent, an aqueous solution with a mannose concentration of 40 g / 100 g was prepared and left to stand at room temperature for 24 hours, after which the weight ratio of α-type to β-type was analyzed by GC. As a result, the ratio of α-type to β-type calculated from the GC area was 67% and 33% (specific rotation [α] D 20 +14.0), which was the ratio of a typical mannose aqueous solution. Next, a test was carried out using the same colon cancer spheroids, except that the glucomannan-derived mannose in Example 1 was replaced with mannose commercially available as a reagent. The results are shown in Figure 1.

[0034] When a significant difference test was performed between Example 1 and Comparative Example 1, the p-value was p=0.007, and it was observed that the mannose of Example 1 had a significantly stronger tumor cell proliferation inhibitory effect. As is clear from Fig. 1, compared with mannose having an α-mannose ratio of less than 70%, mannose having an α-mannose ratio of 70% or more exhibits a stronger cell proliferation inhibitory effect on colon cancer cells. EXAMPLES

[0035] A test was carried out using the same colon cancer spheroids as in Example 1, which is a test using glucomannan-derived mannose in which the ratio of α-mannose to total mannose is 80%, except that the colon cancer spheroid cells were changed from the HC6T strain to the HC106T strain. The results are shown in Figure 2.

[0036] The same test was carried out using colon cancer spheroids, except that the glucomannan-derived mannose in Example 2 was replaced with mannose sold as a reagent in which the ratio of α-mannose to total mannose was 67%. The results are shown in Figure 2.

[0037] When a significant difference test was performed between Example 2 and Comparative Example 2, the p-value was p=0.0000007, and it was observed that the mannose of Example 2 had a significantly stronger tumor cell proliferation inhibitory effect. As is clear from Fig. 2, compared with mannose having an α-mannose ratio of less than 70%, mannose having an α-mannose ratio of 70% or more exhibits a stronger cell proliferation inhibitory effect on colon cancer cells. EXAMPLES

[0038] A test was carried out using the same colon cancer spheroids as in Example 1, which is a test using glucomannan-derived mannose in which the ratio of α-mannose to total mannose is 80%, except that the colon cancer spheroid cells were changed from the HC6T strain to the HC108T strain. The results are shown in Figure 3.

[0039] The same test was carried out using colon cancer spheroids, except that the glucomannan-derived mannose in Example 3 was replaced with mannose sold as a reagent in which the ratio of α-mannose to total mannose was 67%. The results are shown in Figure 3.

[0040] When a significance test was performed between Example 3 and Comparative Example 3, the p-value was p=0.00006, and it was observed that the mannose of Example 3 had a significantly stronger tumor cell proliferation inhibitory effect. As is clear from Fig. 3, compared with mannose having an α-mannose ratio of less than 70%, mannose having an α-mannose ratio of 70% or more exhibits a stronger cell proliferation inhibitory effect on colon cancer cells. As is clear from these examples, mannose with an α-mannose ratio of 70% or more exhibited a very strong cell proliferation inhibitory effect. Therefore, a tumor cell proliferation inhibitor containing mannose with an α-mannose ratio of 70% or more as an active ingredient is presumed to have a high tumor cell proliferation inhibitory effect, and can be expected to be effective even when administered in small amounts to the subject. In particular, the mannose with an α-mannose ratio of 70% or more used in the present invention is derived from a natural product and can be safely ingested or administered.

Claims

1. A tumor cell proliferation inhibitor for use in the prevention and / or treatment of cancer, comprising as an active ingredient at least one hydrolysate selected from the group consisting of mannan, glucomannan, galactomannan and natural products containing them, the hydrolysate comprising mannose in which the ratio of alpha-mannose to total mannose is 70% or more and 80% or less.

2. The tumor cell proliferation inhibitor according to claim 1, wherein the glucomannan is derived from konjac root.

3. The tumor cell proliferation inhibitor according to claim 1, wherein the cancer is a digestive system cancer.

4. The tumor cell proliferation inhibitor according to claim 1, wherein the cancer is colon cancer.

5. A pharmaceutical or quasi-drug for inhibiting tumor cell proliferation, comprising the tumor cell proliferation inhibitor according to claim 1.

6. A food and drink composition for inhibiting tumor cell proliferation, comprising the tumor cell proliferation inhibitor according to claim 1.

Citation Information

Patent Citations

  • Memory controller

    JP1988012072A